|

KRAS Neoantigen Nanovaccine Clinical Trials

1 actively recruiting trial

Also known as: a PD-1/CTLA-4 bispecific antibody

Pipeline

Phase 1/2: 1

Top Sponsors

  • The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School1

Indications

  • Pancreatic Cancer1
  • Colorectal Cancer1
  • Cancer1

Other1 trial

KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer
Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.